A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|June 17, 2025
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.
Advertisement
Host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP, chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee. Finks reviews exactly what concierge medicine is, as well as its role in cardio-kidney-metabolic health and her own research on compounded GLP-1 and GIP agonists in a pharmacist-managed cardiometabolic clinic.
Show Notes:
- Finks SW, Benavides D, Martin AG, Carmon AS.
Real-world observations of using compounded GLP-1 +- GIP agonists within a clinical pharmacist-managed cardiometabolic clinic . J Am Col Clin Pharm. 2024. doi:10.1002/jac5.2071 - Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
Semaglutide and cardiovascular outcomes in obesity without diabetes . N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563 ZupMed.com
Advertisement
Related to this article
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
4
Can AI Help Predict Drug Shortages?
5